Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
affiliate, aimed, aripiprazole, asymptomatic, attachment, autoimmune, autoinjector, bank, Bavarian, BCV, Beclabuvir, beta, calcium, Calibr, certiorari, ClickJect, coinfected, congestive, construct, Dafalgan, device, diversified, docetaxel, downgrade, efficiently, EGFR, ejection, Evotaz, fraction, gene, hazard, heart, IIb, ImClone, innate, intention, issuance, KGaA, kinase, large, master, Medicare, mITT, modulating, mutation, Nordic, Nordisk, Novo, NSCLC, oversight, pharmacoenhanced, platform, post, premium, prespecified, produce, prostate, Prostvac, ratio, reconstitution, regulator, repay, rescind, restore, resubmitted, Rigel, ritonavir, RNA, sBLA, sensor, shown, shutdown, small, snapshot, standpoint, structure, SVR, symptomatic, synthesize, TGF, tier, tiered, timeframe, timetable, Tribunal, Tybost, undetectable, uniQure, valuation, week, writ
Removed:
abbreviated, acceptance, acetate, achieve, Additionally, alleging, annually, approximating, arrangement, assert, Atlantic, breach, Broward, Canadian, centralized, challenged, Chester, clarified, classified, codevelopment, commence, commercialized, compensated, comprised, convert, crystalline, deep, defense, disoproxil, disproxil, Dohme, dynamic, earlier, EMA, embolism, emtricitabine, ending, entirety, environment, exceeded, excluding, executed, exenatide, extension, facilitate, Farxiga, fifteen, fiscal, Florida, focusing, fumarate, hip, impeachment, inability, initially, injectable, interferon, iPierian, IPRD, KIPO, knee, lead, live, lived, long, mandatory, maturing, Measurement, medical, metformin, Ministry, neurodegenerative, newly, nonvalvular, NVAF, orderly, owed, palsy, paper, perform, periodically, Pfizer, polymorph, pramlintide, progressive, pulmonary, pursue, quickly, rapid, reached, receipt, redeemed, reinstatement, removed, restrictive, retroactive, reversal, reversed, SDNY, settle, Sharp, Sheet, Southern, supranuclear, surgery, suspension, systemic, tenofovir, tested, Tort, Truvada, type, undergone, unmet, update, upheld, variable, vein, venture, volume, VTE, vulnerable, warrant, welfare, West
Filing tables
Filing exhibits
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 12.
Computation of Earnings to Fixed Charges
Ratio of Earnings to Fixed Charges: | Three Months Ended March 31, 2015 | Year Ended December 31, | |||||||||||||||||
2014 | 2013 | 2012 | 2011 | ||||||||||||||||
Dollars in Millions | |||||||||||||||||||
Earnings | |||||||||||||||||||
Earnings from continuing operations before income taxes | $ | 1,448 | $ | 2,381 | $ | 2,891 | $ | 2,340 | $ | 6,981 | |||||||||
Less: | |||||||||||||||||||
Noncontrolling interest in pre-tax income of subsidiaries | |||||||||||||||||||
that have not incurred fixed charges | 5 | 38 | 36 | 844 | 2,323 | ||||||||||||||
Equity in net income of affiliates | 26 | 107 | 166 | 183 | 281 | ||||||||||||||
Capitalized interest | 1 | 3 | — | — | — | ||||||||||||||
Adjusted Income | 1,416 | 2,233 | 2,689 | 1,313 | 4,377 | ||||||||||||||
Add: | |||||||||||||||||||
Fixed charges | 63 | 254 | 255 | 227 | 190 | ||||||||||||||
Distributed income of equity investments | 28 | 153 | 149 | 229 | 283 | ||||||||||||||
Total Earnings | $ | 1,507 | $ | 2,640 | $ | 3,093 | $ | 1,769 | $ | 4,850 | |||||||||
Fixed Charges | |||||||||||||||||||
Interest expense | $ | 51 | $ | 203 | $ | 199 | $ | 182 | $ | 145 | |||||||||
Capitalized interest | 1 | 3 | — | — | — | ||||||||||||||
One-third of rental expense(1) | 11 | 48 | 56 | 45 | 45 | ||||||||||||||
Total Fixed Charges | $ | 63 | $ | 254 | $ | 255 | $ | 227 | $ | 190 | |||||||||
Ratio of Earnings to Fixed Charges | 23.92 | 10.39 | 12.13 | 7.79 | 25.53 |
(1) Rents included in the computation consist of one-third of rental expense which the Company believes to be a reasonable estimate of an interest factor in its leases.
E-12-1